Oruka Therapeutics
ORKA
22 hedge funds and large institutions have $6.09M invested in Oruka Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
33% more capital invested
Capital invested by funds: $4.58M → $6.09M (+$1.5M)
26% more call options, than puts
Call options by funds: $165K | Put options by funds: $131K
0.23% more ownership
Funds ownership: 1.29% → 1.51% (+0.23%)
12% less funds holding
Funds holding: 25 → 22 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$108K |
| 2 |
NM
Newtyn Management
New York
|
+$81.8K |
| 3 |
Jane Street
New York
|
+$31.1K |
| 4 |
Renaissance Technologies
New York
|
+$3.61K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$671K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$308K |
| 3 |
SM
SG3 Management
Dorado,
Puerto Rico
|
-$77.7K |
| 4 |
Millennium Management
New York
|
-$77K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$52.2K |
ORKA Hedge Fund Activity: Q4 2022 in Review
22 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2022, worth a combined $6.09M — up 33% from $4.58M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORKA and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Murchinson, opening a new position worth an estimated $108K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $671K sold.
- 22 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2022, down from 25 in Q3 2022.
- Funds reported $6.09M of Oruka Therapeutics stock for Q4 2022, up 33% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q4 2022 and 6 closed out, a net change of -3 holders.
- The largest Oruka Therapeutics buyer in Q4 2022 was Murchinson, an estimated $108K added.
- The largest Oruka Therapeutics seller in Q4 2022 was Susquehanna International Group, an estimated $671K sold.
Based on aggregated 13F filings for Q4 2022.